Differential expression of miR-1297, miR-3191-5p, miR-4435, and miR-4465 in malignant and benign breast tumors

Document Type: Original Article


1 Cancer Research Lab, Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2 Department of Surgery, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran


Objective(s): MicroRNAs (miRs) are a class of small non-coding RNAs which are associated with tumor growth and progression. In the present study, we assessed the expression of selected miRs in malignant, benign, and adjacent normal breast tissues.
Materials and Methods: The expression of miR-1297, miR-3191-5P, miR-4435, and miR-4465 were evaluated in malignant (n=50), benign (n=35), and adjacent normal breast tissues (n=20) using qRT-PCR. Receiver operating characteristic curves and the area under the ROC curve and AUC were generated for evaluating the diagnostic values of miRs. To evaluate diagnostic efficacy, miRs-based score was obtained using the logistic regression model.
Results: Among malignant tumors, the expression of miR-1297, miR-3191-5p, and miR-4435 was significantly lower (P=0.024, PConclusion: The panel of these miRs are suggested as possible onco-miRs(miR-4465) or tumor suppressor-miRs (miR-3191-5P, miR-1297, miR-4435). Overall, our results indicated that these miRs could be introduced as diagnostic biomarkers in breast cancer patients.


1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67:439-448.
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2020;70:7-30.
3. Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol 2018;233:5200-5213.
4. Gholamin S, Mirzaei H. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J Cell Physiol 2018; 233:866-879.
5. Keshavarzi M, Sorayayi S, Jafar Rezaei M, Mohammadi M, Ghaderi A, Rostamzadeh A, et al. MicroRNAs-based imaging techniques in cancer diagnosis and therapy. J Cell Biochem 2017;118:4121-4128.
6. Hashemi ZS, Moghadam MF, Farokhimanesh S, Rajabibazl M, Sadroddiny E. Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics. Iran J Basic Med Sci 2018;21:427-433.
7.    Khani P, Nasri F, Khani Chamani F, Saeidi F, Sadri Nahand J, Tabibkhooei A, et al. Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. J Neurochem 2019;148:188-203.
8.    Mirzaei H, Fathullahzadeh S, Khanmohammadi R, Darijani M, Momeni F, Masoudifar A, et al. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J Cell Physiol 2018;233:888-900.
9. Ranjbarnejad F, Nadri S, Biglari A, Mohammadi Yeganeh S, Paryan M. Effect of let-7a overexpression on the differentiation of conjunctiva mesenchymal stem cells into photoreceptor-like cells. Iran J Basic Med Sci 2019;22:878-883.
10.    Mirzaei H, Ferns GA, Avan A, Mobarhan MG. Cytokines and microRNA in coronary artery disease. Adv Clin Chem 2017;82:47-70.
11.    Mohammadi M, Goodarzi M, Jaafari MR, Mirzaei HR, Mirzaei H. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther 2016; 23: 371-372.
12.    Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009; 35: 328-334.
13.    Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 2016; 76: 3666-3670.
14.    Li F, Lv JH, Liang L, Wang JC, Li CR, Sun L, et al. Downregulation of microRNA-21 inhibited radiation-resistance of esophageal squamous cell carcinoma. Cancer Cell Int 2018; 20: 18-39.
15.    Porzycki P, Ciszkowicz E, Semik M, Tyrka M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol 2018;50:1619-1626.
16.    Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013;59:261-269.
17.    Liu F, He Y, Shu R, Wang S. MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2. Int J Clin Exp Pathol 2015;8:4972-4980.
18.    Sun J, Tian X, Lu S-Q, Hu H-B. MicroRNA-4465 suppresses tumor proliferation and metastasis in non-small cell lung cancer by directly targeting the oncogene EZH2. Biomed Pharmacother 2017;96:1358-1362.
19.    Li X, Wang Hl, Peng X, Zhou Hf, Wang X. MiR-1297 mediates PTEN expression and contributes to cell progression in LSCC. Biochem Biophys Res Commun 2012;427:254-260.
20.    Chen Z, Zhang M, Qiao Y, Yang J, Yin Q. MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN. Artif Cells Nanomed Biotechnol 2018;46:1120-1126.
21.    Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, et al. Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study. Mol Oncol 2014 ;8:874-883.
22.    Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG, et al. MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer 2014;14:1-7.
23.    Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 2016; 107:326-334.
24.    Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013;19:4477-4487.
25.    Pigati L, Yaddanapudi SC, Iyengar R, Kim D-J, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515.
26.    Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol 2011;2011:597145.
27.    Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. MicroRNAs in cancer management. Lancet Oncol 2012;13:249-258.
28.    Wang Y, Yin W, Lin Y, Yin K, Zhou L, Du Y, et al. Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discov 2018;4: 87-95.
29.    Chan M, Liaw CS, Ji SM, Tan HH, Wong C-Y, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013;19:4477-4487.
30.    Chen P, Wang BL, Pan BS, Guo W. MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2. Asian Pac J Cancer Prev. 2014;15:9185-9190.
31.    Çökmüş FP, Özmen E, Alkin T, Batir MB, Çam FS. Evaluation of serum MicroRNA expression profiles in patients with panic disorder. Psychiat Clin Psychopharm 2019;29:8-13.
32.    Gao W, Cao Y, Guo P, Bao X, Zhu H, Zheng J, et al. Downregulation of miR-1297 predicts poor prognosis and enhances gastric cancer cell growth by targeting CREB1. Biomed Pharmacother 2018;105:413-419.
33.    Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, et al. MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 2014;5:1174-1184.
34.    Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther 2017;172:34-49.
35.    Karami-Tehrani F, Malek AR, Shahsavari Z, Atri M. Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors. Tumour Biol. 2016 ;37:8849-8856.
36.    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008;105:10513-10518.
37.    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25:402-408.
38.    Altman DG. Practical statistics for medical research: CRC press; 1990.
39.    He S, Zhang G, Dong H, Ma M, Sun Q. MiR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer. Onco Targets Ther 2016;9:6203-6210.
40.    Tang W, Xu P, Wang H, Niu Z, Zhu D, Lin Q, et al. MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting hMga2. Onco Targets Ther 2018;11:2319-2332.
41.    Li P, Dong J, Zhou X, Sun W, Huang H, Chen T, et al. Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer. Onco Targets Ther 2017;10:5711-5718.
42.    Li C, Zhang J, Ma Z, Zhang F, Yu W. miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther 2018;11:4087-4095.
43.    Liu C, Liu Z, Li X, Tang X, He J, Lu S. MicroRNA-1297 contributes to tumor growth of human breast cancer by targeting PTEN/PI3K/AKT signaling. Oncol Rep 2017;38:2435-2443.
44.    Xing T, Hongtao X, Wenqing Y, Wang B, Zhang J. Expression profiles of microRNA molecules in different stages of chronic hepatitis B virus infection and its clinical significance. Chin J  Infect Dis 2013;31:586-592.
45.    Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Borresen-Dale AL, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res 2015;21:1207-1214.
46.    Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013;132:1602-1612.